Sam joined Inpharmation in 2010 as a financial analyst but was quickly persuaded to transfer his modeling talents to pharmaceuticals. He has been promoted several times, joining the Inpharmation Board in 2021.
As Director of Research and Development, Sam has developed many of Inpharmation’s predictive tools including machine learning algorithms, econometric methods, and conjoint software. An important part of his work is predicting changes in the pharma environment and finding ways to effectively model these for our clients – he has some exciting developments in the pipeline.
Sam runs major research projects for clients in all major therapy areas, all stages of product development, all major HTA systems, and all types of pharmaceuticals – from small molecules to monoclonals and cell and gene therapies.
Sam trains pharma companies across the world on how to forecast and price pharmaceuticals. He is a regular presenter at Europe’s leading pharma training forum: The Centre for Executive Leadership for Pharmaceuticals. Sam also co-authors papers with clients.
Sam has a first-class degree in economics from the University of Manchester.